 |
Hikma, Celltrion reach Truxima licensing agreementHikma Pharmaceuticals has reached a licensing agreement with South Korea-based Celltrion and Celltrion Healthcare for the first biosimilar monoclonal Antibody (mAb) in oncology to be granted European marketing authorisation, Truxima (rituximab). More… |
 |
Hikma to join FTSE 100 index on London SEHikma Pharmaceuticals, a leading multinational pharmaceutical group, will join the FTSE 100 Index, comprising the 100 most highly capitalised blue chip companies listed on the London Stock Exchange, as of March 24. Mazen Darwazah, More… |
|
Hikma to join FTSE 100 index on London SEHikma Pharmaceuticals, a leading multinational pharmaceutical group, will join the FTSE 100 Index, comprising the 100 most highly capitalised blue chip companies listed on the London Stock Exchange, as of March 24. Mazen Darwazah, More… |
 |
Hikma opens oncology plant in JordanHikma Pharmaceuticals, a multinational group, recently opened its chemical plant for oncology active pharmaceutical ingredients (API) specialised in producing effective raw materials for cancer medications. The plant was inaugurat More… |
 |
Hikma H1 revenue up 16pc to $738mHikma Pharmaceuticals, a major multinational pharmaceutical group with operations across Mena, Europe and the US, reported a 16 per cent increase in Group revenue to $738 million during first six months of the year. The increase i More… |
 |
Hikma H1 revenue up 20pc to $638mHikma Pharmaceuticals, a top multinational pharmaceutical group, has reported revenue of $638.3 million in the first half of 2013, reflecting a 19.9 per cent increase over the same period last year. The Group is expected to delive More… |
 |
Hikma Pharma to spend $300m on expansionLondon-listed Hikma Pharmaceuticals plans to spend nearly $300 million on acquisitions and expansion initiatives in 2012 amid strong growth prospects in the Middle East and North Africa, its chief financial officer said. "In terms of acqui More… |
 |
Hikma Pharma H1 sales up 10pcJordanian pharma company Hikma saw its first-half revenue surge 10.4 per cent despite problems in other North African and Middle East markets due to a strong sales in Algeria, Sudan and Iraq. Hikma, which sells both generic and b More… |
 |
Hikma sees revenue growthJordanian drugmaker Hikma Pharmaceuticals said it expected first-half revenue to grow around 40 per cent. Hikma also said in a trading update, ahead of the release of results for the first half of 2007 on September 5, it was confident of d More… |
